Endocrine News and Research

RSS

Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc., has been granted orphan-drug designation by the U.S. Food and Drug Administration for perifosine, Aeterna Zentaris' novel, potentially first-in-class, oral Akt inhibitor, for the treatment of neuroblastoma.

15 Jul 2010

Kinetico's in-home water filtration options decrease exposure to carcinogens

In its most recent annual report, the President's Cancer Panel lists in-home water filtration as a way to decrease exposure to both known and suspected carcinogens as well as endocrine disruptors. Kinetico's line of in-home treatment options provides multiple resources for water filtration, in line with the PCP's recommended solution to lower in-home exposure to carcinogens.

14 Jul 2010

Manuscript based on study of Clarient InsightDx Mammostrat to be published in Breast Cancer Research

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that a manuscript based on a study of Clarient InsightDx Mammostrat, a test used to classify the risk of recurrence of breast cancer following surgery and chemotherapy, will be published in an upcoming edition of Breast Cancer Research, a prominent peer-reviewed medical journal.

12 Jul 2010

Patients with hyperglycaemia during acute illness have increased risk of developing diabetes: Researchers

Hyperglycemia during critical illness may be used as a warning of future diabetes. Researchers writing in BioMed Central's open access journal Critical Care have found a significant association between acute illness complicated with hyperglycaemia and the future development of type II diabetes or glucose intolerance.

8 Jul 2010

Researchers develop first model of hormone-induced human prostate cancer initiation and progression

Progress toward understanding the role of sex hormones in the growth of prostate cancer—the most common cancer in U.S. men—has been hindered by the lack of a suitable laboratory research model. Now researchers say they have developed the first model of hormone-induced human prostate cancer initiation and progression.

2 Jul 2010

Diabetics need more 'heat awareness'

Hot weather and diabetes can make for a potentially dangerous combination, according to a Mayo Clinic presentation at the 92nd Annual Meeting of the Endocrine Society in San Diego, California, June 19-22.

2 Jul 2010

Vitamin D inadequacy may cause metabolic syndrome among elderly people

A new study adds to the mounting evidence that older adults commonly have low vitamin D levels and that vitamin D inadequacy may be a risk factor for the metabolic syndrome, a condition that affects one in four adults. The results were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

2 Jul 2010

Older men with high testosterone levels more likely to have heart attacks

A large U.S. multicenter study shows that older men with higher testosterone levels are more likely to have a heart attack or other cardiovascular disease in the future. The results were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

2 Jul 2010

New asthma therapy shows promise for patients who do not respond to steroid treatments

A new nonsteroidal, anti-inflammatory therapy made from a human protein significantly decreases disease signs of asthma in mice, opening the possibility of a new asthma therapy for patients who do not respond to current steroid treatments. Results of this therapy in an animal model were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

2 Jul 2010

Individual variants of environmental toxins can affect body's hormone systems: Research

Marianne Kraugerud's doctoral research has led to the discovery that individual variants of the environmental pollutants PCB and PFC can affect several of the body's hormone systems in a more complex way than previously supposed. Humans and animals are constantly exposed to these toxins through the food they eat and the air they breathe. Kraugerud concludes that the impact of these pollutants should be taken into account when carrying out risk appraisals of PCB and PFC.

1 Jul 2010

Bisphenol A (BPA) containing baby bottles to be phased out

Federal Parliamentary Secretary for Health Mark Butler has announced that following public concern and a safety review ordered by US health regulators, the phase out will begin from today. He also revealed that according to Food Standards Australia New Zealand intake levels are very low and do not pose a risk to babies' health.

1 Jul 2010

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.

30 Jun 2010

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

29 Jun 2010

Blood test to help predict when women will hit menopause

Researchers have developed a way of accurately predicting when women will hit the menopause using a simple blood test. The average difference between the predicted age and the actual age that the women in their study reached the menopause was only a third of a year, and the maximum margin of error was between three and four years.

28 Jun 2010

Aeterna Zentaris, Almac collaborate on study of AEZS-108 doxorubicin LHRH targeted conjugate compound

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced a collaborative study with Almac's Diagnostics division for the Company's doxorubicin luteinizing hormone-releasing hormone (LHRH) targeted conjugate compound, AEZS-108, aimed at determining LHRH receptor expression through the development of a companion diagnostic tool.

28 Jun 2010

Linagliptin mono- and combination therapy improves blood glucose control

Linagliptin phase III data were presented for the first time this week at the 70th Scientific Sessions of the American Diabetes Association (ADA), showing that this investigational compound, a dipeptidyl peptidase (DPP)-4 inhibitor, achieved significant, sustained and clinically meaningful reductions in blood glucose as measured by haemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and postprandial glucose (PPG) concentrations.(1-6) Linagliptin is being investigated by Boehringer Ingelheim as a once-daily oral treatment in type 2 diabetes.

28 Jun 2010

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American Diabetes Association Scientific Sessions.

28 Jun 2010

Pregnant women with thyroid hormone levels on upper end of normal at increased risk for miscarriage

Pregnant women with thyroid function test results in the upper half of the normal range have an increased chance of miscarriage, even when they lack thyroid-harming antibodies, according to a new study. The results, which the authors say show the need to change screening practices for pregnant women, will be presented at The Endocrine Society's 92nd Annual Meeting, ENDO 2010, in San Diego on June 22 by Alex Stagnaro-Green, M.D., senior author and senior associate dean for education at The George Washington University School of Medicine and Health Sciences.

24 Jun 2010

FDA schedules Advisory Committee meeting to review Orexigen's Contrave NDA

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 to review the Company's New Drug Application (NDA) for Contrave® (naltrexone sustained release (SR)/bupropion SR) for the treatment of obesity.

24 Jun 2010

Endocrine Society presents Scientific Statement on menopausal hormone therapy at ENDO 2010

The Endocrine Society presented its Scientific Statement on menopausal hormone therapy Monday in San Diego, Calif. at ENDO 2010: The 92nd Annual Meeting & Expo.

23 Jun 2010

Endocrine News and Research

Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma

Kinetico's in-home water filtration options decrease exposure to carcinogens

Manuscript based on study of Clarient InsightDx Mammostrat to be published in Breast Cancer Research

Patients with hyperglycaemia during acute illness have increased risk of developing diabetes: Researchers

Researchers develop first model of hormone-induced human prostate cancer initiation and progression

Diabetics need more 'heat awareness'

Vitamin D inadequacy may cause metabolic syndrome among elderly people

Older men with high testosterone levels more likely to have heart attacks

New asthma therapy shows promise for patients who do not respond to steroid treatments

Individual variants of environmental toxins can affect body's hormone systems: Research

Bisphenol A (BPA) containing baby bottles to be phased out

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

Blood test to help predict when women will hit menopause

Aeterna Zentaris, Almac collaborate on study of AEZS-108 doxorubicin LHRH targeted conjugate compound

Linagliptin mono- and combination therapy improves blood glucose control

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Pregnant women with thyroid hormone levels on upper end of normal at increased risk for miscarriage

FDA schedules Advisory Committee meeting to review Orexigen's Contrave NDA

Endocrine Society presents Scientific Statement on menopausal hormone therapy at ENDO 2010

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News